Cencora

(New York Stock Exchange)
Back to all articles
Bullish +75

Cencora (COR) Stock After Healthcare Supply Chain Reassessment Is The Market Overreacting - simplywall.st

AI-generated analysis

πŸ“‰ Cencora stock has declined 15.3% year-to-date but gained 5.6% in the past week, closing at US$286.95.

πŸ’° A Discounted Cash Flow (DCF) analysis projects an intrinsic value of US$484.52 per share.

πŸ“Š The current price implies a significant 40.8% discount to the calculated intrinsic value based on future cash flows.

πŸ” Cencora trades at a P/E ratio of 21.91x, which is lower than the industry average of 23.67x and peer average of 29.56x.

πŸ“ˆ The company's proprietary 'Fair Ratio' is estimated at 24.74x, further indicating undervaluation relative to growth and risk profiles.

πŸ₯ Cencora sources and distributes pharmaceutical products in the United States and internationally.

πŸ’΅ The stock is described as very undervalued with a solid track record and dividend payments.

Bullish Signals
  • Cencora's share price implies a 40.8% discount to its estimated intrinsic value of US$484.52 per share based on DCF analysis.
  • The company trades at a P/E ratio of 21.91x, which is below the Healthcare industry average of 23.67x and peer group average of 29.56x.
  • Cencora has a solid track record and pays a dividend, adding to its investment appeal.
  • The stock is described as 'very undervalued' with strong fundamentals supporting a higher fair value.
Full Analysis
Cencora (COR) stock recently closed at US$286.95, reflecting a 15.3% decline year-to-date but significant gains over the past week and month. The article argues that recent market reassessments of healthcare supply chain companies may be causing an overreaction to Cencora's current valuation. Using a Discounted Cash Flow (DCF) model based on last twelve months free cash flow of approximately $1.66 billion, the estimated intrinsic value is calculated at US$484.52 per share. This implies a substantial 40.8% discount to the current trading price, suggesting the stock is undervalued relative to its projected future cash flows. Valuation metrics further support this view, with Cencora trading at a P/E ratio of 21.91x, which is below both the Healthcare industry average of 23.67x and its peer group average of 29.56x. The company's proprietary 'Fair Ratio' is estimated at 24.74x, indicating the stock appears undervalued even when adjusting for specific growth and risk characteristics. The article concludes that Cencora offers a compelling value proposition with a solid track record and dividend payments, positioning it as a potentially attractive investment despite recent share price weakness compared to peers.